 So there's a few things that are unique about Organova as a company, and the first is that we sit at the interface of a number of different technical disciplines, and it really took an advancement in getting all these disciplines to work together to get to some of the technical opportunities that we've had. So we bring together mechanical engineering, software engineering, and cell biology in a way where we can create innovative 3D bioprinting solutions. If we didn't have that, I think people would still rely on old tools like putting cells in a Petri dish or on a plate and working with them and not have some of the breakthroughs that we're seeing with our technology today. At Organova, we're seeing breakthroughs in a number of different areas, so every time we apply the 3D bioprinting technology to a new tissue, we see things that haven't been achievable before working in that area of biology in the lab. Because we can recreate functional human tissue outside the body, you can start to learn things about certain biological areas that you can't see using just cells in a dish. So we've worked in areas like lung tissue, liver tissue, and kidney, and in each area we see some breakthroughs that haven't been achieved before. There are many attributes of an innovative company, and at Organova we evidence a few of those. One of the key ones is having a sense of mission. So everyone at Organova is motivated by having an impact on patients eventually. In the short term, we're working on that by offering innovative new drug models that can be better than animal models and get to new drugs for patients in urgent need. But over the long term, we also hope to offer tissues that are useful when transplanted into patients to treat a specific medical condition. And that drives all of us every day because we get incoming requests for people, can you treat this condition yet with 3D bioprinting? It's really powerful for us to keep that motivation and keep focused on the end goals of achieving wins for patients. So Organova can impact some pretty big global health problems. One of the problems we have today is the failure rate of new drugs. So we've all heard it very many times that you'll make it all the way to phase three with a specific drug only to have it fail in human trials. And that comes at great cost, and it takes a lot of time to get to that point. By offering a better predictive model of disease outside the body with a 3D bioprinted human tissue, you can change that paradigm, which is driven by the over reliance on animal models. So if we can do a better job of picking the right molecules using Organova's bioprinted human tissues, you have a chance to offer solutions for patients at a lower cost and faster. That's very important. Drugs like drugs for Alzheimer's disease, which have been attempted to date, have failed many times in late stage clinicals due to unforeseen liver toxicity. And so we're building 3D liver tissue, for example, to help with that problem.